{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T01:41:59Z","timestamp":1785634919129,"version":"3.56.0"},"reference-count":110,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Parkinson\u2019s Disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide, with significant economic and social implications. The increasing prevalence of PD, coupled with rising healthcare costs, necessitates cost-effective solutions for patient management. Wearable medical devices, such as STAT-ON\u2122, an inertial sensor with AI processing capability, offer an opportunity to enhance symptom monitoring, optimize therapy adjustments, and improve patient quality of life (QoL). However, their cost-effectiveness in routine clinical practice remains insufficiently explored. This study conducts a cost-benefit analysis of integrating STAT-ON\u2122 into European healthcare systems (Spain, Sweden, Germany, Italy, and the UK). Using validated clinical data, we assess the economic impact of early symptom detection facilitated by continuous monitoring. Our findings suggest that improved symptom assessment can lead to optimized medication regimens, reducing hospitalizations and institutional care costs. While medication costs may increase, overall direct healthcare expenses decrease, leading to net savings. As an example, the study estimates potential cost reductions of up to \u20ac137.8 million in Germany and \u20ac19 million in Sweden when STAT-ON\u2122 is used to detect advanced PD symptoms. Despite these promising results, limitations exist, including variations in healthcare costs, reimbursement policies, and real-world adoption rates across the different countries. Additionally, indirect costs such as caregiver burden were not fully analyzed. Future longitudinal studies are needed to further validate the economic and clinical benefits of wearable monitoring devices in PD management. This study highlights the potential of STAT-ON\u2122 as a valuable tool for reducing healthcare costs and enhancing patient outcomes, supporting its adoption as a complementary solution for objective PD assessment in clinical practice.<\/jats:p>","DOI":"10.1371\/journal.pone.0334413","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:33:12Z","timestamp":1760117592000},"page":"e0334413","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improving Parkinson\u2019s disease management through wearable technology: A cost-benefit perspective"],"prefix":"10.1371","volume":"20","author":[{"given":"Daniel","family":"Rodriguez-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-1955","authenticated-orcid":true,"given":"Andreu","family":"Catal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Cabestany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"1","key":"pone.0334413.ref001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"R Balestrino","year":"2020","journal-title":"Eur J Neurol"},{"key":"pone.0334413.ref002","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"ER Dorsey","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"pone.0334413.ref003","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"D Su","year":"2025","journal-title":"BMJ"},{"key":"pone.0334413.ref004","unstructured":"European Parkinson\u2019s Disease Association. The European Parkinson\u2019s disease standards of care consensus statement; 2011. 28 p. Available from: https:\/\/www.epda.eu.com\/media\/1181\/epda-consensus-statement-en.pdf"},{"issue":"1","key":"pone.0334413.ref005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"CDBE2010 study group","year":"2012","journal-title":"Eur J Neurol"},{"issue":"7","key":"pone.0334413.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180425","article-title":"Hospitalization and rehospitalization in Parkinson disease patients: data from the National Parkinson Foundation Centers of Excellence","volume":"12","author":"L Shahgholi","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"pone.0334413.ref007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/CPJ.0000000000000746","article-title":"Symptom burden among individuals with Parkinson disease: a national survey","volume":"10","author":"CG Tarolli","year":"2020","journal-title":"Neurol Clin Pract"},{"issue":"9","key":"pone.0334413.ref008","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3390\/s20092713","article-title":"Wearable solutions for patients with Parkinson\u2019s disease and neurocognitive disorder: a systematic review","volume":"20","author":"A Channa","year":"2020","journal-title":"Sensors (Basel)"},{"key":"pone.0334413.ref009","article-title":"How mobile health technology and electronic health records will change care of patients with Parkinson\u2019s disease","volume":"8","author":"C Hansen","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"pone.0334413.ref010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-bioeng-062117-121036","article-title":"New sensor and wearable technologies to aid in the diagnosis and treatment monitoring of Parkinson\u2019s disease","volume":"21","author":"MHG Monje","year":"2019","journal-title":"Annu Rev Biomed Eng"},{"issue":"12","key":"pone.0334413.ref011","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/mds.25628","article-title":"Quantitative wearable sensors for objective assessment of Parkinson\u2019s disease","volume":"28","author":"W Maetzler","year":"2013","journal-title":"Mov Disord"},{"key":"pone.0334413.ref012","first-page":"1","article-title":"Motor abilities analysis using a standardized tapping test enhanced by a detailed processing stage: gender and age comparison","author":"T Di Libero","year":"2023","journal-title":"2023 IEEE International Symposium on Medical Measurements and Applications (MeMeA). IEEE"},{"issue":"2","key":"pone.0334413.ref013","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/s22020409","article-title":"A sensor-based perspective in early-stage Parkinson\u2019s disease: current state and the need for machine learning processes","volume":"22","author":"MG Krokidis","year":"2022","journal-title":"Sensors (Basel)"},{"key":"pone.0334413.ref014","doi-asserted-by":"crossref","first-page":"912343","DOI":"10.3389\/fneur.2022.912343","article-title":"A new paradigm in Parkinson\u2019s disease evaluation with wearable medical devices: a review of STAT-ONTM","volume":"13","author":"D Rodr\u00edguez-Mart\u00edn","year":"2022","journal-title":"Front Neurol"},{"key":"pone.0334413.ref015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.compbiomed.2017.03.020","article-title":"Estimating bradykinesia severity in Parkinson\u2019s disease by analysing gait through a waist-worn sensor","volume":"84","author":"A Sam\u00e0","year":"2017","journal-title":"Comput Biol Med"},{"issue":"2","key":"pone.0334413.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171764","article-title":"Home detection of freezing of gait using support vector machines through a single waist-worn triaxial accelerometer","volume":"12","author":"D Rodr\u00edguez-Mart\u00edn","year":"2017","journal-title":"PLoS One"},{"key":"pone.0334413.ref017","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.patrec.2017.05.009","article-title":"Determining the optimal features in freezing of gait detection through a single waist accelerometer in home environments","volume":"105","author":"A Sam\u00e0","year":"2018","journal-title":"Pattern Recognit Lett"},{"issue":"2","key":"pone.0334413.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171764","article-title":"Home detection of freezing of gait using support vector machines through a single waist-worn triaxial accelerometer","volume":"12","author":"D Rodr\u00edguez-Mart\u00edn","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"pone.0334413.ref019","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/s16122132","article-title":"Assessing motor fluctuations in Parkinson\u2019s disease patients based on a single inertial sensor","volume":"16","author":"C P\u00e9rez-L\u00f3pez","year":"2016","journal-title":"Sensors (Basel)"},{"key":"pone.0334413.ref020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fneur.2017.00431","article-title":"Analysis of correlation between an accelerometer-based algorithm for detecting Parkinsonian gait and UPDRS subscales","volume":"8","author":"A Rodr\u00edguez-Molinero","year":"2017","journal-title":"Front Neurol"},{"issue":"1","key":"pone.0334413.ref021","doi-asserted-by":"crossref","DOI":"10.2196\/mhealth.3321","article-title":"Validation of a portable device for mapping motor and gait disturbances in Parkinson\u2019s disease","volume":"3","author":"A Rodr\u00edguez-Molinero","year":"2015","journal-title":"JMIR Mhealth Uhealth"},{"key":"pone.0334413.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gaitpost.2017.09.031","article-title":"A \u201cHOLTER\u201d for Parkinson\u2019s disease: validation of the ability to detect on-off states using the REMPARK system","volume":"59","author":"\u00c0 Bay\u00e9s","year":"2018","journal-title":"Gait Posture"},{"key":"pone.0334413.ref023","article-title":"Clinical utility of a personalized and long-term monitoring device for Parkinson\u2019s disease in a real clinical practice setting: An expert opinion survey on STAT-ON\u2122","author":"D Santos Garc\u00eda","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"key":"pone.0334413.ref024","doi-asserted-by":"crossref","first-page":"835249","DOI":"10.3389\/fneur.2022.835249","article-title":"Comparison of the results of a Parkinson\u2019s Holter monitor with patient diaries, in real conditions of use: a sub-analysis of the MoMoPa-EC clinical trial","volume":"13","author":"C P\u00e9rez-L\u00f3pez","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"pone.0334413.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279910","article-title":"Feasibility of a wearable inertial sensor to assess motor complications and treatment in Parkinson\u2019s disease","volume":"18","author":"N Caballol","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"pone.0334413.ref026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.neuarg.2021.05.006","article-title":"Evaluaci\u00f3n de un sistema de sensores inerciales externos tipo Holter en pacientes con enfermedad de Parkinson en Argentina","volume":"13","author":"F Perrote","year":"2021","journal-title":"Neurol Argent"},{"key":"pone.0334413.ref027","article-title":"Improving the patient self-awareness of the first motor fluctuations in early Parkinson\u2019s disease with a wearable sensor.","volume-title":"Movement disorders","author":"N Caballol","year":"2022"},{"key":"pone.0334413.ref028","first-page":"1","article-title":"Exploring the morning akinesia in Parkinson\u2019s disease with the wearable sensor STAT-ON.","volume-title":"Movement disorders","author":"N Caballol","year":"2022"},{"key":"pone.0334413.ref029","doi-asserted-by":"crossref","first-page":"1249385","DOI":"10.3389\/fneur.2023.1249385","article-title":"Holter STAT-ON\u2122 against other tools for detecting MF in advanced Parkinson\u2019s disease: an observational study","volume":"14","author":"I Cabo-Lopez","year":"2023","journal-title":"Front Neurol"},{"key":"pone.0334413.ref030","first-page":"100325","article-title":"Comparison of clinical measures of motor function with a Holter monitor in Parkinson\u2019s disease","volume":"12","author":"C P\u00e9rez-L\u00f3pez","year":"2025","journal-title":"Clin Park Relat Disord"},{"issue":"5","key":"pone.0334413.ref031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/bioengineering11050440","article-title":"Unveiling the unpredictable in Parkinson\u2019s disease: sensor-based monitoring of dyskinesias and freezing of gait in daily life","volume":"11","author":"A Zampogna","year":"2024","journal-title":"Bioengineering (Basel)"},{"key":"pone.0334413.ref032","doi-asserted-by":"crossref","DOI":"10.1201\/9781032632865","author":"J Cabestany","year":"2023","journal-title":"A Holter for Parkinson\u2019s disease motor symptoms: STAT-On\u2122. New York: River Publishers"},{"key":"pone.0334413.ref033","article-title":"Improving awareness of motor fluctuations in Parkinson\u2019s disease: an educational patient support program using a waist-worn device.","volume-title":"Movement disorders","author":"N Caballol","year":"2024"},{"issue":"1","key":"pone.0334413.ref034","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41531-025-00977-2","article-title":"Parkinson\u2019s disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial","volume":"11","author":"A Rodr\u00edguez-Molinero","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"pone.0334413.ref035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia","volume":"23","author":"RA Hauser","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"pone.0334413.ref036","article-title":"Unified Parkinson\u2019s disease rating scale for.","volume-title":"Recent developments in Parkinson\u2019s disease","author":"Members of the UPDRS Development Committee","year":"1987"},{"issue":"5","key":"pone.0334413.ref037","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1755-5949.2011.00253.x","article-title":"Patient diaries as a clinical endpoint in Parkinson\u2019s disease clinical trials","volume":"18","author":"SS Papapetropoulos","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"pone.0334413.ref038","doi-asserted-by":"crossref","first-page":"935664","DOI":"10.3389\/fneur.2022.935664","article-title":"Objective observer vs. patient motor state assessments using the pd home diary in advanced Parkinson\u2019s disease","volume":"13","author":"J Timpka","year":"2022","journal-title":"Front Neurol"},{"issue":"6","key":"pone.0334413.ref039","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1212\/01.CPJ.0000437018.37541.eb","article-title":"Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease: ITALY","volume":"3","author":"A Albanese","year":"2013","journal-title":"Neurol Clin Pract"},{"issue":"5","key":"pone.0334413.ref040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1474-4422(19)30397-7","article-title":"Long-term unsupervised mobility assessment in movement disorders","volume":"19","author":"E Warmerdam","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"pone.0334413.ref041","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","article-title":"Early detection of wearing off in Parkinson disease: the DEEP study","volume":"20","author":"F Stocchi","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"pone.0334413.ref042","first-page":"1","article-title":"DISCREPA study: treatment of advanced Parkinson\u2019s disease and use of second-line treatments in Catalonia","volume":"72","author":"A \u00c1vila","year":"2021","journal-title":"Rev Neurol"},{"issue":"12","key":"pone.0334413.ref043","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/brainsci11121557","article-title":"Prevalence of advanced Parkinson\u2019s disease in patients treated in the hospitals of the Spanish national healthcare system: the PARADISE study","volume":"11","author":"JC Mart\u00ednez-Castrillo","year":"2021","journal-title":"Brain Sci"},{"issue":"1","key":"pone.0334413.ref044","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","article-title":"Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients","volume":"19","author":"A Fasano","year":"2019","journal-title":"BMC Neurol"},{"issue":"2","key":"pone.0334413.ref045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/ane.13434","article-title":"Swedish guidelines for device-aided therapies in Parkinson\u2019s disease -economic evaluation and implementation","volume":"144","author":"JM Norlin","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"22","key":"pone.0334413.ref046","article-title":"Association of motor and nonmotor symptoms with health-related quality of life in a large online cohort of people with Parkinson disease","volume":"98","author":"MA Bock","year":"2022","journal-title":"Neurology"},{"issue":"8","key":"pone.0334413.ref047","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","article-title":"Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease","volume":"21","author":"J Jankovic","year":"2007","journal-title":"CNS Drugs"},{"issue":"2","key":"pone.0334413.ref048","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11310940-000000000-00000","article-title":"Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson\u2019s disease","volume":"24","author":"A Antonini","year":"2010","journal-title":"CNS Drugs"},{"issue":"8","key":"pone.0334413.ref049","first-page":"503","article-title":"Advanced Parkinson\u2019s disease: clinical characteristics and treatment (part 1)","volume":"28","author":"J Kulisevsky","year":"2013","journal-title":"Neurologia"},{"key":"pone.0334413.ref050","first-page":"480260","article-title":"Treatment of advanced Parkinson\u2019s disease","volume":"2010","author":"S Varanese","year":"2011","journal-title":"Parkinsons Dis"},{"issue":"6","key":"pone.0334413.ref051","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.27340","article-title":"Medical and surgical management of advanced Parkinson\u2019s disease","volume":"33","author":"A Antonini","year":"2018","journal-title":"Mov Disord"},{"key":"pone.0334413.ref052","first-page":"4047392","article-title":"Consensus on the definition of advanced Parkinson\u2019s disease: a neurologists-based Delphi study (CEPA study)","volume":"2017","author":"M-R Luquin","year":"2017","journal-title":"Parkinsons Dis"},{"issue":"12","key":"pone.0334413.ref053","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","article-title":"Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach","volume":"34","author":"A Antonini","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"pone.0334413.ref054","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JPD-191765","article-title":"Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s disease patients","volume":"10","author":"C Cattaneo","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"pone.0334413.ref055","doi-asserted-by":"crossref","first-page":"754016","DOI":"10.3389\/fneur.2021.754016","article-title":"The added benefit of opicapone when used early in Parkinson\u2019s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II","volume":"12","author":"J-F Rocha","year":"2021","journal-title":"Front Neurol"},{"key":"pone.0334413.ref056","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2020.06.236","article-title":"Efficacy\/safety of opicapone in Parkinson\u2019s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II","volume":"79","author":"G Ebersbach","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"pone.0334413.ref057","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","article-title":"Rotigotine transdermal patch: a review in Parkinson\u2019s disease","volume":"33","author":"JE Frampton","year":"2019","journal-title":"CNS Drugs"},{"issue":"9463","key":"pone.0334413.ref058","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"O Rascol","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"pone.0334413.ref059","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group","volume":"51","author":"UK Rinne","year":"1998","journal-title":"Neurology"},{"issue":"9","key":"pone.0334413.ref060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations","volume":"33","author":"F Carbone","year":"2019","journal-title":"CNS Drugs"},{"issue":"9","key":"pone.0334413.ref061","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"R Katzenschlager","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"pone.0334413.ref062","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.parkreldis.2012.06.022","article-title":"Duodopa\u00ae treatment for advanced Parkinson\u2019s disease: a review of efficacy and safety","volume":"18","author":"D Nyholm","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"pone.0334413.ref063","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00702-018-1906-0","article-title":"Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease","volume":"125","author":"A Antonini","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"pone.0334413.ref064","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000113714","article-title":"Duodenal levodopa infusion improves quality of life in advanced Parkinson\u2019s disease","volume":"5","author":"A Antonini","year":"2008","journal-title":"Neurodegener Dis"},{"issue":"9","key":"pone.0334413.ref065","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00415-018-8951-3","article-title":"Assessment of Duodopa\u00ae effects on quality of life of patients with advanced Parkinson\u2019s disease and their caregivers","volume":"265","author":"R Ciurleo","year":"2018","journal-title":"J Neurol"},{"key":"pone.0334413.ref066","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.parkreldis.2020.10.029","article-title":"A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson\u2019s disease","volume":"81","author":"ES Farbman","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0334413.ref067","doi-asserted-by":"crossref","first-page":"17562864221108018","DOI":"10.1177\/17562864221108018","article-title":"Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance","volume":"15","author":"D Nyholm","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"pone.0334413.ref068","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"MJ Soileau","year":"2022","journal-title":"Lancet Neurol"},{"key":"pone.0334413.ref069","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41531-020-0115-3","article-title":"Long-term Parkinson\u2019s disease quality of life after staged DBS: STN vs GPi and first vs second lead","volume":"6","author":"S Cernera","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"pone.0334413.ref070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","article-title":"Long-term outcomes of deep brain stimulation in Parkinson disease","volume":"15","author":"P Limousin","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"pone.0334413.ref071","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","article-title":"Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis","volume":"36","author":"A Antonini","year":"2022","journal-title":"CNS Drugs"},{"key":"pone.0334413.ref072","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5004","article-title":"Physiotherapy intervention in Parkinson\u2019s disease: systematic review and meta-analysis","volume":"345","author":"CL Tomlinson","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"pone.0334413.ref073","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1545968320952799","article-title":"Physiotherapy in Parkinson\u2019s disease: a meta-analysis of present treatment modalities","volume":"34","author":"DLM Radder","year":"2020","journal-title":"Neurorehabil Neural Repair"},{"key":"pone.0334413.ref074","first-page":"3257623","article-title":"Effect of exercise on quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"2020","author":"K Chen","year":"2020","journal-title":"Parkinsons Dis"},{"issue":"5","key":"pone.0334413.ref075","first-page":"529","article-title":"Effect of exercise on perceived quality of life of individuals with Parkinson\u2019s disease","volume":"37","author":"J Baatile","year":"2000","journal-title":"J Rehabil Res Dev"},{"issue":"8","key":"pone.0334413.ref076","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/mdc3.13089","article-title":"Efficacy of occupational therapy interventions on quality of life in patients with Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"7","author":"M Tofani","year":"2020","journal-title":"Mov Disord Clin Pract"},{"issue":"10","key":"pone.0334413.ref077","doi-asserted-by":"crossref","DOI":"10.1016\/j.apmr.2021.07.570","article-title":"Cognitive stimulation therapy for people with Parkinson\u2019s disease dementia","volume":"102","author":"K Storey","year":"2021","journal-title":"Arch Phys Med Rehabil"},{"key":"pone.0334413.ref078","doi-asserted-by":"crossref","first-page":"1756286419852217","DOI":"10.1177\/1756286419852217","article-title":"Parkinson\u2019s-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial","volume":"12","author":"I Leroi","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"pone.0334413.ref079","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1468-1331.2002.00484.x","article-title":"The importance of educational and psychological factors in Parkinson\u2019s disease quality of life","volume":"9","author":"E Cubo","year":"2002","journal-title":"Eur J Neurol"},{"issue":"3","key":"pone.0334413.ref080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1590\/1980-57642015dn93000013","article-title":"Evaluation of quality of life and psychological aspects of Parkinson\u2019s disease patients who participate in a support group","volume":"9","author":"NR Artigas","year":"2015","journal-title":"Dement Neuropsychol"},{"issue":"7","key":"pone.0334413.ref081","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00415-022-10969-4","article-title":"Personalizing decision-making for persons with Parkinson\u2019s disease: where do we stand and what to improve?","volume":"269","author":"L van den Heuvel","year":"2022","journal-title":"J Neurol"},{"key":"pone.0334413.ref082","first-page":"108","volume-title":"Parkinson \u2019 s disease: global drug forecast and market analysis to 2026","author":"GlobalData","year":"2018"},{"key":"pone.0334413.ref083","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2010.04.011","article-title":"Trends in resource utilization for Parkinson\u2019s disease in Germany","volume":"294","author":"Y Winter","year":"2010","journal-title":"J Neurol Sci"},{"issue":"12","key":"pone.0334413.ref084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145310","article-title":"Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis","volume":"10","author":"P Martinez-Mart\u00edn","year":"2015","journal-title":"PLoS One"},{"key":"pone.0334413.ref085","unstructured":"Cubo E, Mart\u00ednez Mart\u00edn P, Gonz\u00e1lez M, Frades B, Members of the ELEP group. Impact of motor and non-motor symptoms on the direct costs of Parkinson\u2019s disease. Available from: www.ine.es (Spanish version)"},{"issue":"5","key":"pone.0334413.ref086","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/ane.13502","article-title":"Parkinson\u2019s disease in Sweden-resource use and costs by severity","volume":"144","author":"F Hjalte","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"pone.0334413.ref087","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.28265","article-title":"Burden of Parkinson\u2019s disease by severity: health care costs in the U.S. medicare population","volume":"36","author":"N Dahodwala","year":"2021","journal-title":"Mov Disord"},{"key":"pone.0334413.ref088","first-page":"9106026","article-title":"Direct cost of Parkinson\u2019s disease: a real-world data study of second-line therapies","volume":"2020","author":"E Gomez-Inhiesto","year":"2020","journal-title":"Parkinsons Dis"},{"issue":"12","key":"pone.0334413.ref089","doi-asserted-by":"crossref","first-page":"529","DOI":"10.33588\/rn.6312.2016160","article-title":"Estudio farmacoecon\u00f3mico del tratamiento de la enfermedad de Parkinson avanzada","volume":"63","author":"F Vivancos Matellano","year":"2016","journal-title":"RevNeurol"},{"issue":"2","key":"pone.0334413.ref090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3111\/13696998.2012.737392","article-title":"Cost analysis of the treatments for patients with advanced Parkinson\u2019s disease: SCOPE study","volume":"16","author":"Workgroup of the SCOPE study","year":"2013","journal-title":"J Med Econ"},{"issue":"1","key":"pone.0334413.ref091","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","article-title":"Caregiver-burden in parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability","volume":"12","author":"A Schrag","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"pone.0334413.ref092","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mds.27579","article-title":"The long-term direct and indirect economic burden among Parkinson\u2019s disease caregivers in the United States","volume":"34","author":"P Martinez-Martin","year":"2019","journal-title":"Mov Disord"},{"issue":"9","key":"pone.0334413.ref093","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1468-1331.2010.02984.x","article-title":"Longitudinal study of the socioeconomic burden of Parkinson\u2019s disease in Germany","volume":"17","author":"Y Winter","year":"2010","journal-title":"Eur J Neurol"},{"issue":"2","key":"pone.0334413.ref094","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.euroneuro.2010.08.002","article-title":"Costs of illness and care in Parkinson\u2019s disease: an evaluation in six countries","volume":"21","author":"S von Campenhausen","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"pone.0334413.ref095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000302644","article-title":"Costs of Parkinson\u2019s disease and antiparkinsonian pharmacotherapy: an Italian cohort study","volume":"7","author":"Y Winter","year":"2010","journal-title":"Neurodegener Dis"},{"issue":"10","key":"pone.0334413.ref096","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/mds.10507","article-title":"Direct economic impact of Parkinson\u2019s disease: a research survey in the United Kingdom","volume":"18","author":"L Findley","year":"2003","journal-title":"Mov Disord"},{"issue":"1","key":"pone.0334413.ref097","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3111\/13696998.2010.551164","article-title":"The economic burden of advanced Parkinson\u2019s disease: an analysis of a UK patient dataset","volume":"14","author":"LJ Findley","year":"2011","journal-title":"J Med Econ"},{"issue":"7","key":"pone.0334413.ref098","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ner.12474","article-title":"Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States","volume":"19","author":"JB Pietzsch","year":"2016","journal-title":"Neuromodulation"},{"issue":"2","key":"pone.0334413.ref099","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3233\/JPD-202348","article-title":"Cost-effectiveness of device-aided therapies in Parkinson\u2019s disease: a structured review","volume":"11","author":"K Smilowska","year":"2021","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"pone.0334413.ref100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13696998.2018.1553179","article-title":"Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales","volume":"22","author":"S Kalabina","year":"2019","journal-title":"J Med Econ"},{"issue":"1","key":"pone.0334413.ref101","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/13696998.2021.1916750","article-title":"Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson\u2019s disease patients treated with levodopa\/carbidopa","volume":"24","author":"RN Hansen","year":"2021","journal-title":"J Med Econ"},{"key":"pone.0334413.ref102","article-title":"Long-term extrapolation of safinamide clinical efficacy in mid- to late-stage Parkinson\u2019s disease patients","author":"A Antonini","year":"2014","journal-title":"NMDPD 2014, the 10th International Congress on Non-Motor Dysfunctions in Parkinson\u2019s Disease and Related Disorders"},{"issue":"9","key":"pone.0334413.ref103","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11316770-000000000-00000","article-title":"Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson\u2019s disease in the UK setting: an economic Markov model evaluation","volume":"26","author":"A Haycox","year":"2009","journal-title":"Drugs Aging"},{"issue":"4","key":"pone.0334413.ref104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1524-4733.2001.004004316.x","article-title":"Cost-effectiveness analysis of entacapone in Parkinson\u2019s disease: a Markov process analysis","volume":"4","author":"MJ Nuijten","year":"2001","journal-title":"Value Health"},{"issue":"11","key":"pone.0334413.ref105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ijcp.12844","article-title":"Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson\u2019s disease","volume":"70","author":"AH Heald","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"1","key":"pone.0334413.ref106","doi-asserted-by":"crossref","DOI":"10.2196\/rehab.8335","article-title":"A kinematic sensor and algorithm to detect motor fluctuations in Parkinson disease: validation study under real conditions of use","volume":"5","author":"A Rodr\u00edguez-Molinero","year":"2018","journal-title":"JMIR Rehabil Assist Technol"},{"issue":"4","key":"pone.0334413.ref107","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ana.26612","article-title":"An apple a day to keep the Parkinson\u2019s disease doctor away?","volume":"93","author":"BR Bloem","year":"2023","journal-title":"Ann Neurol"},{"issue":"12","key":"pone.0334413.ref108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260889","article-title":"Adopting a multidisciplinary telemedicine intervention for fall prevention in Parkinson\u2019s disease. Protocol for a longitudinal, randomized clinical trial","volume":"16","author":"E Cubo","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"pone.0334413.ref109","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16561","article-title":"Cost-utility analysis of a coadjutant telemedicine intervention for fall prevention in Parkinson\u2019s disease","volume":"32","author":"E Cubo","year":"2025","journal-title":"Eur J Neurol"},{"issue":"7","key":"pone.0334413.ref110","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s10389-023-02082-1","article-title":"Virtual coach and telerehabilitation for Parkinson\u00b4s disease patients: vCare system","volume":"33","author":"R Del Pino","year":"2023","journal-title":"J Public Health (Berl)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:33:28Z","timestamp":1760117608000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334413"}},"subtitle":[],"editor":[{"given":"Joel","family":"Montan\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":110,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334413","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}